Publications by authors named "Larry Shen"

Claim this Profile
E
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
John A Hey, Susan Abushakra, Kaj Blennow, Eric M Reiman, Jakub Hort, Larry Shen

Drugs· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Design for Decision Rules Based on Statistical Testing Strategies of Binary Endpoints in a Definitive Go/No-Go Single-Treatment Clinical Study.
Ming Zhou, Larry Z Shen

Ther Innov Regul Sci· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
Börje Darpö, Philip Sager, Leigh MacConell, Brenda Cirincione, Malcolm Mitchell, Larry Shen

Br J Clin Pharmacol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.
Robert Ratner, Jenny Han, Dawn Nicewarner, Irina Yushmanova, Byron J Hoogwerf, Larry Shen

Cardiovasc Diabetol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
Mark Fineman, Shawn Flanagan, Kristin Taylor, Maria Aisporna, Larry Z Shen

Clin Pharmacokinet· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
Louis J Aronne, Amy E Halseth, Colleen M Burns, Stephan Miller, Larry Z Shen

Obesity (Silver Spring)· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
John B Buse, Daniel J Drucker, Kristin L Taylor, Terri Kim, Brandon Walsh, Larry Z Shen

Diabetes Care· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Bayesian approach to utilizing prior data in new drug development.
Larry Z Shen, Todd Coffey, Wei Deng

J Biopharm Stat· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study.
Terri Poon, Patric Nelson, Larry Shen, Michael Mihm, Kristin Taylor

Diabetes Technol Ther· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Properties of pramlintide and insulin upon mixing.
Christian Weyer, Mark S Fineman, Susan Strobel, Larry Shen, Joann Data

Am J Health Syst Pharm· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
Mark S Fineman, Larry Z Shen, Kristin Taylor, Dennis D Kim, Alain D Baron

Diabetes Metab Res Rev· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
Orville G Kolterman, Dennis D Kim, Larry Shen, James A Ruggles, Loretta L Nielsen

Am J Health Syst Pharm· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
Priscilla Hollander, David G Maggs, James A Ruggles, Mark Fineman, Larry Shen

Obes Res· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
Mark S Fineman, Thomas A Bicsak, Larry Z Shen, Kristin Taylor, Eling Gaines

Diabetes Care· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
Priscilla A Hollander, Philip Levy, Mark S Fineman, David G Maggs, Larry Z Shen

Diabetes Care· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles

Diabetes Care· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis